Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children

Kabataş, Emrah Utku; Kurtul, Bengi Ece; Özer, Pınar Altiaylik; Kabataş, Naciye

doi:10.1080/02713683.2016.1264607

Cited by 38 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An analysis of the two groups showed that the gestational age and birth weight were significantly lower in the anti-VEGF treatment group than that in the laser treatment group. This result is similar to other reports [ 8 , 44 , 53 – 57 ].…”

Section: Discussionsupporting

confidence: 93%

“…Retinal laser photocoagulation is a standard treatment for ROP. However, it can result in many problems, such as a wide range of retinal damage and the loss of vision in the photocoagulation area, and is not suitable for some patients, such as those with ROP in zone 1 or AP-ROP [ 44 – 46 ]. Anti-VEGF drugs may reduce complications when treating ROP.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units

et al. 2018

View full text Add to dashboard Cite

BackgroundRetinopathy of prematurity (ROP) is a vascular proliferative disorder of the developing retina and a significant cause of childhood blindness around the world. The incidence of ROP is affected by many factors, and the incidence rate varies from country to country. The purpose of this study is to report the incidence and risk factors of ROP in neonatal intensive care unit (NICU) of Guangzhou First People’s Hospital in China.MethodsA retrospective review was performed on 436 premature infants who were consecutive ROP screened in the NICU of Guangzhou First People’s Hospital from March 2013 to October 2017. The single-factor analysis and the logistic multivariate regression analysis were used to detect risk factors of ROP.ResultsTotal 436 premature infants were consecutive ROP screened, 138 (31.65%) were found ROP, and 61(13.99%) were treated. The single-factor analysis revealed that the incidence of ROP was associated with multiple births, gestational age, birth weight, mechanical ventilation, intravascular hemolysis, the number of operations and blood culture results. The logistic multivariate regression analysis revealed that gestational age; birth weight, mechanical ventilation, minimum SaO2 and daily weight gain were independent risk factors for ROP onset. Forty-nine patients underwent retinal laser photocoagulation with recurrence 20 patients. Twelve patients underwent anti-VEGF drug (Ranibizumab) via intraocular injection with 5 patients of recurrence.ConclusionsThe incidence of ROP in NICU of Guangzhou China will match those in middle-income countries, but higher than high-income countries. Anti-VEGF drugs could be preferred as a good treatment method for zone 1 ROP and aggressive posterior ROP.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units

et al. 2018

View full text Add to dashboard Cite

show abstract

“…They could not find a difference between the two groups. Kabataş et al [27] investigated the effects of bevacizumab, ranibizumab, and laser photocoagulation for the treatment of ROP. They found that treated eyes had a more myopic refraction than spontaneously regressed eyes.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1

Kimyon

Mete²

2018

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To investigate the effects of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP) affecting zone 1. Methods: Files of the patients who received intravitreal bevacizumab (IVB) or ranibizumab (IVR) treatment for ROP affecting zone 1 were evaluated retrospectively. Spherical equivalent (SE) and axial length (AXL) measurements were performed at 1 year of adjusted age. Results: Sixty-eight eyes of 37 patients were included in the study. All patients had initial disease regression but 6 patients (4 in the IVB, 2 in the IVR group) showed reactivation (p = 0.679). The number of eyes with incomplete vascularization were 15 and 12 in the IVB and IVR groups, respectively (p = 0.725). Mean AXL was 20.50 ± 0.99 mm in the IVB group and 19.30 ± 0.48 mm in the IVR group (p < 0.001). Mean SE was –1.49 ± 2.38 dpt in the IVB group and 0.98 ± 2.18 dpt in the IVR group (p < 0.001). Conclusion: Bevacizumab and ranibizumab showed similar effectiveness in the treatment of type 1 ROP affecting zone 1. The AXL was longer and SE was more myopic in eyes treated with IVB. This difference might be caused by the longer intravitreal half-life of bevacizumab than ranibizumab.

show abstract

“…Intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibodies is an alternative to laser treatment in severe cases of ROP, such as aggressive posterior ROP (APROP), and ROP in zone 1 or posterior zone 2 [6]. Different from laser treatment, anti-VEGF antibody injection may allow maturation of the peripheral retina and anterior segment, and reports indicate better structural and visual outcomes (median VA of 0.3 log-MAR at around 2 years after treatment for type 1 ROP [7]) and a reduced incidence of myopia compared with laser [6,[8][9][10][11][12][13][14][15][16], though not all studies support these findings [17,18]. Anti-VEGF antibody therapy may require more than one treatment application, with reported retreatment rates ranging from 4 to 14% [6,9,11,12], though higher rates of 27% have also been reported [7].…”

Section: Introductionmentioning

confidence: 99%

Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes

Adams

Bunce

Xing

et al. 2018

Eye

View full text Add to dashboard Cite

show abstract

Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children

Abstract: IVB, IVR and LP are options that can successfully treat ROP. Myopia was observed to be the main refractive error in all treatment groups. Vascularization of the retina was completed later in the IVB group than in the IVR group.

Cited by 38 publications

References 22 publications

The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units

The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units

Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1

Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes

Contact Info

Product

Resources

About